Clareo Health | Post-Marketing Safety Study of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA-1273 COVID-19 Vaccine in the United States
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
ModernaTX, Inc.
This retrospective observational cohort study will use secondary, de-identified individual-level medical and pharmacy claims data provided by HealthVerity.
Age
Any age
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
Included in a health plan covered by HealthVerity database
Covered by a health plan during at least 1 period of interest (pre-COVID-19, active-COVID-19, and post-EUA periods), but not necessarily the full period.
Demonstrate an AESI specified clean period of continuous baseline enrollment or activity before the period of interest (pre-COVID-19, active-COVID-19, and post-EUA periods) during which the participant is covered.
